Sensei Biotherapeutics is a clinical-stage immunotherapy company that engages in the discovery and development of next generation therapies with a primary focus on the treatments for cancer. Its proprietary ImmunoPhage™ platform is a self-adjuvanted and differentiated immunotherapy approach designed to use bacteriophage to induce a focused and coordinated innate and adaptive immune response.
The company is driven by scientists and an entrepreneurial culture that focus on rigorous science, innovative treatments, and data-driven decision making, it discovers and develops medicines that possess the potential to alter the treatment landscape and add value to patients and society. The company has developed a drug discovery approach, ImmunoPhage, that generates specific immune responses.
Its lead program, SNS-301, targets the tumor antigen, Aspartyl beta Hydroxylase (ASPH), and is in an ongoing Phase 1/2 trial in combination with pembrolizumab for the treatment of Squamous Cell Carcinoma of the Head and Neck (SCCHN). The company has more programs in several stages of preclinical development.